Annual CFO
$4.96 B
-$2.27 B-31.40%
March 31, 2024
Summary
- As of February 7, 2025, TAK annual cash flow from operations is $4.96 billion, with the most recent change of -$2.27 billion (-31.40%) on March 31, 2024.
- During the last 3 years, TAK annual CFO has fallen by -$4.57 billion (-47.94%).
- TAK annual CFO is now -50.38% below its all-time high of $10.00 billion, reached on March 31, 2022.
Performance
TAK Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
$2.44 B
+$490.73 M+25.22%
December 1, 2024
Summary
- As of February 7, 2025, TAK quarterly cash flow from operations is $2.44 billion, with the most recent change of +$490.73 million (+25.22%) on December 1, 2024.
- Over the past year, TAK quarterly CFO has increased by +$490.73 million (+25.22%).
- TAK quarterly CFO is now -34.08% below its all-time high of $3.70 billion, reached on March 31, 2021.
Performance
TAK Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
$7.47 B
+$1.49 B+24.87%
December 1, 2024
Summary
- As of February 7, 2025, TAK TTM cash flow from operations is $7.47 billion, with the most recent change of +$1.49 billion (+24.87%) on December 1, 2024.
- Over the past year, TAK TTM CFO has increased by +$1.49 billion (+24.87%).
- TAK TTM CFO is now -27.24% below its all-time high of $10.27 billion, reached on December 31, 2021.
Performance
TAK TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
TAK Cash From Operations Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -31.4% | +25.2% | +24.9% |
3 y3 years | -47.9% | +2.0% | +3.3% |
5 y5 years | +67.5% | -34.1% | -21.6% |
TAK Cash From Operations Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -50.4% | at low | -28.9% | +274.8% | -27.2% | +50.6% |
5 y | 5-year | -50.4% | +67.5% | -34.1% | +274.8% | -27.2% | +50.6% |
alltime | all time | -50.4% | +2236.9% | -34.1% | +304.4% | -27.2% | +925.9% |
Takeda Pharmaceutical Company Limited Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | - | $2.44 B(+25.2%) | $7.47 B(+24.9%) |
Sep 2024 | - | $1.95 B(+78.1%) | $5.99 B(+11.2%) |
Jun 2024 | - | $1.09 B(-45.4%) | $5.38 B(+8.4%) |
Mar 2024 | $4.96 B(-31.4%) | $2.00 B(+110.9%) | $4.96 B(-7.3%) |
Dec 2023 | - | $948.05 M(-29.4%) | $5.35 B(-24.0%) |
Sep 2023 | - | $1.34 B(+99.5%) | $7.04 B(-3.0%) |
Jun 2023 | - | $673.38 M(-71.8%) | $7.26 B(+0.3%) |
Mar 2023 | $7.24 B(-27.7%) | $2.39 B(-9.5%) | $7.24 B(-12.6%) |
Dec 2022 | - | $2.64 B(+69.2%) | $8.28 B(-3.5%) |
Sep 2022 | - | $1.56 B(+139.9%) | $8.58 B(-6.0%) |
Jun 2022 | - | $650.14 M(-81.0%) | $9.13 B(-8.7%) |
Mar 2022 | $10.00 B(+4.9%) | $3.43 B(+16.5%) | $10.00 B(-2.6%) |
Dec 2021 | - | $2.94 B(+39.4%) | $10.27 B(+8.4%) |
Sep 2021 | - | $2.11 B(+38.4%) | $9.48 B(-2.4%) |
Jun 2021 | - | $1.52 B(-58.8%) | $9.71 B(+1.8%) |
Mar 2021 | $9.54 B(+54.8%) | $3.70 B(+72.2%) | $9.54 B(+26.3%) |
Dec 2020 | - | $2.15 B(-8.2%) | $7.55 B(+13.1%) |
Sep 2020 | - | $2.34 B(+72.5%) | $6.68 B(+4.0%) |
Jun 2020 | - | $1.36 B(-20.7%) | $6.42 B(+4.2%) |
Mar 2020 | $6.16 B(+108.0%) | $1.71 B(+34.1%) | $6.16 B(+11.1%) |
Dec 2019 | - | $1.27 B(-38.8%) | $5.55 B(+9.0%) |
Sep 2019 | - | $2.08 B(+89.4%) | $5.09 B(+37.8%) |
Jun 2019 | - | $1.10 B(+0.7%) | $3.69 B(+24.6%) |
Mar 2019 | $2.96 B(-13.1%) | $1.09 B(+34.0%) | $2.96 B(-2.8%) |
Dec 2018 | - | $814.36 M(+18.7%) | $3.05 B(+3.0%) |
Sep 2018 | - | $686.11 M(+84.9%) | $2.96 B(-4.8%) |
Jun 2018 | - | $371.06 M(-68.5%) | $3.11 B(-8.8%) |
Mar 2018 | $3.41 B(+41.1%) | $1.18 B(+62.2%) | $3.41 B(+0.5%) |
Dec 2017 | - | $726.34 M(-13.0%) | $3.39 B(+19.9%) |
Sep 2017 | - | $834.79 M(+24.4%) | $2.83 B(+8.1%) |
Jun 2017 | - | $671.11 M(-42.3%) | $2.62 B(+8.3%) |
Mar 2017 | $2.42 B | $1.16 B(+615.4%) | $2.42 B(+3751.0%) |
Dec 2016 | - | $162.48 M(-73.9%) | $62.76 M(-88.1%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2016 | - | $621.96 M(+32.3%) | $527.15 M(-0.3%) |
Jun 2016 | - | $470.08 M(-139.4%) | $528.82 M(+148.9%) |
Mar 2016 | $212.43 M(-87.3%) | -$1.19 B(-290.1%) | $212.43 M(-88.0%) |
Dec 2015 | - | $626.87 M(+0.5%) | $1.77 B(+8.2%) |
Sep 2015 | - | $623.64 M(+305.8%) | $1.63 B(-4.3%) |
Jun 2015 | - | $153.69 M(-57.5%) | $1.70 B(+2.1%) |
Mar 2015 | $1.67 B(+12.4%) | $361.45 M(-26.7%) | $1.67 B(-29.4%) |
Dec 2014 | - | $493.12 M(-29.2%) | $2.37 B(+2.4%) |
Sep 2014 | - | $696.63 M(+491.2%) | $2.31 B(-7.9%) |
Jun 2014 | - | $117.83 M(-88.9%) | $2.51 B(+68.9%) |
Mar 2014 | $1.48 B(-63.1%) | $1.06 B(+142.3%) | $1.48 B(+247.7%) |
Dec 2013 | - | $436.63 M(-51.2%) | $427.06 M(-4563.4%) |
Sep 2013 | - | $895.35 M(-198.9%) | -$9.57 M(-98.9%) |
Jun 2013 | - | -$904.92 M(-170.9%) | -$904.92 M(-123.8%) |
Mar 2013 | $4.02 B(-5.6%) | - | - |
Mar 2012 | $4.26 B(+12.3%) | - | - |
Mar 2011 | $3.80 B(-7.6%) | $1.28 B(+62.0%) | $3.80 B(+4.4%) |
Dec 2010 | - | $787.48 M(-39.9%) | $3.64 B(-4.7%) |
Sep 2010 | - | $1.31 B(+210.2%) | $3.82 B(+1.9%) |
Jun 2010 | - | $422.68 M(-62.1%) | $3.75 B(-8.8%) |
Mar 2010 | $4.11 B(+25.2%) | $1.12 B(+15.7%) | $4.11 B(+37.3%) |
Dec 2009 | - | $965.04 M(-22.3%) | $2.99 B(+47.6%) |
Sep 2009 | - | $1.24 B(+58.1%) | $2.03 B(+158.1%) |
Jun 2009 | - | $785.33 M | $785.33 M |
Mar 2009 | $3.28 B(+27.8%) | - | - |
Mar 2008 | $2.57 B(+43.4%) | - | - |
Mar 2007 | $1.79 B(-45.8%) | - | - |
Mar 2006 | $3.30 B(+20.0%) | - | - |
Mar 2005 | $2.75 B(-0.2%) | - | - |
Mar 2004 | $2.76 B(+27.5%) | - | - |
Mar 2003 | $2.16 B(+12.3%) | - | - |
Mar 2002 | $1.93 B(-0.0%) | - | - |
Mar 2001 | $1.93 B(+34.4%) | - | - |
Mar 2000 | $1.43 B | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual cash flow from operations?
- What is the all time high annual CFO for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual CFO year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly cash flow from operations?
- What is the all time high quarterly CFO for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly CFO year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM cash flow from operations?
- What is the all time high TTM CFO for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM CFO year-on-year change?
What is Takeda Pharmaceutical Company Limited annual cash flow from operations?
The current annual CFO of TAK is $4.96 B
What is the all time high annual CFO for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual cash flow from operations is $10.00 B
What is Takeda Pharmaceutical Company Limited annual CFO year-on-year change?
Over the past year, TAK annual cash flow from operations has changed by -$2.27 B (-31.40%)
What is Takeda Pharmaceutical Company Limited quarterly cash flow from operations?
The current quarterly CFO of TAK is $2.44 B
What is the all time high quarterly CFO for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly cash flow from operations is $3.70 B
What is Takeda Pharmaceutical Company Limited quarterly CFO year-on-year change?
Over the past year, TAK quarterly cash flow from operations has changed by +$490.73 M (+25.22%)
What is Takeda Pharmaceutical Company Limited TTM cash flow from operations?
The current TTM CFO of TAK is $7.47 B
What is the all time high TTM CFO for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM cash flow from operations is $10.27 B
What is Takeda Pharmaceutical Company Limited TTM CFO year-on-year change?
Over the past year, TAK TTM cash flow from operations has changed by +$1.49 B (+24.87%)